Mitsubishi buys into Fujifilm's contract biologics manufacturing ops
This article was originally published in Scrip
Another major Japanese trading house has taken a step into the contract manufacturing of biologics, this time through the acquisition of a stake in two former Merck & Co operations purchased recently by Fujifilm.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.